about
Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours.TLX activates MMP-2, promotes self-renewal of tumor spheres in neuroblastoma and correlates with poor patient survival.HIF2A and IGF2 expression correlates in human neuroblastoma cells and normal immature sympathetic neuroblasts.Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancersNeuroblastoma aggressiveness in relation to sympathetic neuronal differentiation stage.Myc-induced glutaminolysis bypasses HIF-driven glycolysis in hypoxic small cell lung carcinoma cells.PI3K-mTORC2 but not PI3K-mTORC1 regulates transcription of HIF2A/EPAS1 and vascularization in neuroblastoma.Differential regulation of HIF-1α and HIF-2α in neuroblastoma: Estrogen-related receptor alpha (ERRα) regulates HIF2A transcription and correlates to poor outcome.Hypoxia, pseudohypoxia and cellular differentiation.The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.The PI3-kinase isoform p110δ is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner.No reason to reconsider HIF-2 as an oncogene in neuroblastoma and other cancer forms.Hypoxia and hypoxia-inducible factors in neuroblastoma.Promoter-associated proteins of EPAS1 identified by enChIP-MS - A putative role of HDX as a negative regulator.A Novel Topical PPARγ Agonist Induces PPARγ Activity in Ulcerative Colitis Mucosa and Prevents and Reverses Inflammation in Induced Colitis Models.Tumor-Initiating Cells in Childhood Neuroblastoma--LetterEnhanced expression of MycN/CIP2A drives neural crest toward a neural stem cell-like fate: Implications for priming of neuroblastomaMaintaining multipotent trunk neural crest stem cells as self-renewing crestospheresAnti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastomaAnti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma
P50
Q34438553-38D8C2B5-E9D1-4010-A6AD-52016A81BF69Q34541693-9062296C-3CE0-43B1-BEF7-2336E6CB14E0Q36670909-C3F9CFE1-884E-444B-9AA0-F8DBC92F1F12Q37336207-EEB970E4-D9B8-4A14-8D91-7199B9535B45Q37938377-DF70C5DB-ABA8-4C1A-8150-5B4ED9CD5F26Q38826776-81FD8B91-BE64-4D26-88E1-64BFCF9CE7C9Q38830637-55BA39EE-4546-4594-AAAC-694A2AEA5940Q38882410-60F66870-62DC-4ACA-A5C0-83FDC7B0304EQ38913214-C94177B6-67D6-425B-9036-2737B9C586F6Q38936739-08963165-E87D-4BC3-93B6-079A279B5347Q39064868-3431E2A6-F7D1-429E-99E7-CB6A55D13853Q49886828-D2F9B71E-E203-42CA-B3C8-3BB0C730B653Q50070013-E5F0F13E-C33C-4F9B-8840-35C6B59F6D80Q52431024-6F2623C8-3536-450C-AC41-92567A9DBC05Q52660691-E43D9CF9-110A-48EE-B548-EEACC01E5CF6Q59879984-BF28272C-8A67-446A-8AF9-93BCDCE32493Q90321088-0FA8273F-5BDD-45AA-AB35-413CBE100492Q91143582-F8D8A78C-749A-43CD-ACEE-97EA1ACD2755Q91918375-A982AB1C-6AAE-48EE-B3E0-7E4238FECDDFQ92509850-109F3F20-A5FE-4977-AB19-F80446622CE9
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sofie Mohlin
@ast
Sofie Mohlin
@en
Sofie Mohlin
@es
Sofie Mohlin
@nl
Sofie Mohlin
@sl
type
label
Sofie Mohlin
@ast
Sofie Mohlin
@en
Sofie Mohlin
@es
Sofie Mohlin
@nl
Sofie Mohlin
@sl
prefLabel
Sofie Mohlin
@ast
Sofie Mohlin
@en
Sofie Mohlin
@es
Sofie Mohlin
@nl
Sofie Mohlin
@sl
P106
P108
P1153
54382293200
P21
P31
P496
0000-0002-2458-3963